Investor Insights highlights some of the top investors in Life Science and MedTech. This week host Ken Dropiewski interviews Tom Hertzberg, Managing Director, Lifesciences and Healthcare, Silicon Valley BanK https://vimeo.com/626976813
Author: Ken Dropiewski
NEW RESEARCH FINDS CHALLENGES IN SYMPTOM RECOGNITION AND DIAGNOSTIC TESTING CAN IMPACT PATIENT SATISFACTION FOR PEOPLE WITH VASCULAR DISEASE
– One in four physicians surveyed feel the “lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease” is a key obstacle to an accurate diagnosis – Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease […]
AngelMed Announces CMS Approval of Transitional Pass-Through (TPT) Payment Category For The Guardian™ Effective January 1, 2022
EATONTOWN, N.J., Nov. 11, 2021 /PRNewswire/ — Angel Medical Systems, Inc., (dba AngelMed) a company focused on improving long-term management of high-risk coronary disease in patients who have survived one or more heart attacks, announced today the Center for Medicare & Medicaid Services (CMS) has granted The Guardian™ implantable acute coronary syndrome […]
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
If approved, Jardiance would be the first clinically proven treatment for adults across the full spectrum of heart failure regardless of ejection fraction RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 11, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 […]
BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2021 and filed its quarterly report on Form 10-Q for the three and nine months […]
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2021 and provided key business updates. “I am very pleased to […]
Stereotaxis Reports 2021 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2021. “We are proud of the progress made on multiple fronts in the third quarter,” said David […]
HeartBeam Announces Pricing of $16.5 Million Initial Public Offering
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, today announced the pricing of its initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one […]
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the initiation of VICTOR (VerICiguaT in adults with ChrOnic heart failure and Reduced ejection fraction), a pivotal Phase 3 randomized, placebo-controlled cardiovascular clinical trial of VERQUVO® (vericiguat) in patients with chronic heart failure and reduced ejection fraction of 40% […]
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
Announced topline data from Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old Reached interim enrollment milestone for the REVERSE-IT Phase 3 trial of bentracimab Prespecified interim analysis of pivotal REVERSE-IT Phase 3 trial to be presented during late-breaking science session on November […]
Recent
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Brainomix AI Imaging Analysis of Phase 3 CHARM Trial Identifies Promising Treatment Signals in Severe Stroke Patients
In the New HelloNation Feature, Healthcare Expert Justin Doss of Beaumont Explains Heart Attack vs. Cardiac Arrest
Popular
- No commented posts yet